The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

According to Nice, osimertinib can help stop cancer from returning after surgery by targeting cells that have specific ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

is under clinical development by biopharmaceutical company AstraZeneca and is currently in a Phase III study. The drug candidate is administered orally in the form of a film-coated tablet and acts ...

Since it was launched six years ago, the government’s drug bidding process, known as volume-based procurement, has seen off-patent medicines from global pharmaceutical giants such as AstraZeneca ...

As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...

A breakthrough daily pill which doubles the survival time for certain lung cancer patients will now be routinely available on ...